Developing innovative therapies for disorders of the Ear, Nose and Throat (ENT)
Novus Therapeutics is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each with the potential to be developed for multiple indications.
Our lead program (OP0201) is a surfactant-based nasal aerosol drug-device combination product candidate being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media, which is middle ear inflammation and effusion with or without infection. Globally, otitis media (OM) affects more than 700 million adults and children every year, with over half of the cases occurring in children under five years of age. OM is one of the most common disorders seen in pediatric practice, and in the U.S. is a leading cause of health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery.
Additionally, we have a foam-based drug delivery technology platform (OP01xx), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.